<DOC>
	<DOCNO>NCT01322152</DOCNO>
	<brief_summary>The objective study evaluate efficacy tolerability single-week regimen irinotecan plus capecitabine first-line second-line treatment advance colorectal cancer .</brief_summary>
	<brief_title>Study Irinotecan Plus Capecitabine Treat Advanced Colorectal Cancer</brief_title>
	<detailed_description>Irinotecan capecitabine approve effective drug advance colorectal cancer patient . However , combination two drug regularly recommend due severe diarrhea common adverse event.This study design explore whether single-week regimen irinotecan plus capecitabine improves efficacy increase toxicity advance colorectal cancer patient China .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Signed informed consent Histologically confirm colorectal cancer Age 1870 year old Advanced colorectal cancer patient , firstline secondline treatment , adjuvant treatment include oxaliplatin or/and 5FU finish six month Have least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . ECOG 01 Life expectancy 3 month . Normal laboratory value : hemoglobin &gt; 90g/dl , neutrophil &gt; 1.5×10^9/L , platelet &gt; 100×10^9/L , serum creatinine &lt; 1.5×upper limit normal ( ULN ) , serum bilirubin &lt; 1.5×ULN , ALT AST &lt; 2.5×ULN , AKP &lt; 4×ULN Pregnant lactate patient Concurrent disease condition would make subject inappropriate study participation , serious medical disorder would interfere subject 's safety Active uncontrolled infection Known history uncontrolled symptomatic angina , arrhythmia , congestive heart failure Patients could swallow tablet Concomitant brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>metastasis</keyword>
	<keyword>neoplasm</keyword>
</DOC>